4 citations
,
July 2013 in “Journal of Dermatological Science” This study found that interleukin-10 deficiency in B6 mice led to inflammatory milk production due to maternal stress, causing alopecia and hepatocyte steatosis in pups.
3 citations
,
October 2024 in “Archives of Dermatological Research” Salivary vitamin D and IL-6 could help diagnose and manage non-scarring alopecia.
3 citations
,
September 2024 in “Experimental Dermatology” This study found elevated levels of IL-18 and free IL-18 in hidradenitis suppurativa patients compared to healthy controls, suggesting these cytokines may serve as novel biomarkers for disease activity, with correlations indicating their involvement in disease severity.
3 citations
,
January 2023 in “JEADV Clinical Practice” This study suggests that IL-17 may play a more significant role than IFN-γ in the pathogenesis of chronic alopecia areata, with increasing severity linked to Th17 lymphocytes and cytotoxic T lymphocyte infiltration.
3 citations
,
May 2020 in “JAAD Case Reports” This report discusses two patients with plaque psoriasis who developed hypertrichosis, or excessive hair growth, while undergoing interleukin-17A inhibitor therapy.
3 citations
,
May 2017 in “Heliyon” This study found that in a neonatal rat model, skin wounding protected against chemotherapy-induced alopecia through IL-1β signaling, making hair follicles more resistant to damage when wounding exposure was timed correctly.
2 citations
,
December 2024 in “Gene Reports” This study found that serum IL-37 levels were significantly elevated in alopecia areata patients compared to healthy controls and correlated with the severity of the condition, though no link was found between IL-37 gene polymorphism (rs3811047) and the risk of developing the disease.
2 citations
,
February 2024 in “Medicine” In this study, researchers found that the rs3118470 mutation in the IL2RA gene significantly increases the risk of developing alopecia areata, and they emphasize the need for future research with larger, more diverse populations to validate these results.
2 citations
,
January 2024 in “Advances in Dermatology and Allergology” This study suggests a potential role for S100A7 and IL-17 in the pathogenesis of lichen planopilaris.
2 citations
,
June 2018 in “The Medical Journal of Cairo University/The Medical Journal of Cairo University” This study found that while Platelet Rich Plasma injections led to some clinical and immunological improvements in psoriatic plaques, it could not be recommended as a standalone treatment for localized plaque psoriasis.
1 citations
,
May 2025 in “Fayoum University Medical Journal/Fayoum University Medical Journal ” This systematic review reported an association between specific interleukin gene polymorphisms (IL-17A, IL-18, IL17RA, and IL16) and alopecia areata, suggesting further genetic studies are needed to confirm the interleukins' role in the disorder's progression.
1 citations
,
July 2024 in “British Journal of Dermatology” This study found that inhibiting EGFR and MEK in hair follicles may lead to a partial collapse of the immune privilege in the follicles and increased secretion of IL-33.
1 citations
,
April 2024 in “Journal of Autoimmunity” This study found that rhIL-15 promotes human hair follicle growth and regrowth in experimental settings and may have therapeutic potential for alopecia areata by restoring immune privilege guardianship.
1 citations
,
July 2012 in “Nasza Dermatologia Online” This study found that patients with alopecia areata had significantly higher serum levels of IL-1α compared to healthy controls, with no significant difference observed in IL-1β levels.
1 citations
,
October 2005 in “Experimental and Clinical Endocrinology & Diabetes” This study found that in pregnant rats, the suppression of ACTH responses to IL-1β is linked to the action of endogenous opioids and AP, with AP potentially inducing opioid inhibition through increased pENK-A expression.
June 2026 in “Research Square” June 2026 in “Immunity Inflammation and Disease” In this study, researchers observed that dandruff involves altered keratinocyte activity and a low-grade inflammatory response characterized by increased interleukin-17-producing T-cells and CCL17 levels, but without significant changes in immune cell populations or skin barrier lipids.
March 2026 in “European journal of ecology, biology and agriculture.” This study found significantly higher levels of Toll-Like Receptor 4, interferon gamma, and interleukin-17 in Iraqi patients with alopecia areata compared to controls, suggesting these immune markers play a crucial role in the disease's development and could be targets for future treatments.
January 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” This study observed that male patients with alopecia areata had elevated serum levels of HSP70 and IL-15, with levels increasing alongside disease severity, suggesting these markers are strongly associated with the disease's pathogenesis.
October 2025 in “Cell Proliferation” In laboratory research, investigators found that apoptotic vesicles from interleukin-10-treated fibroblasts promote wound healing and reduce fibrotic scarring by enhancing mitochondrial function, modulating collagen composition, and inhibiting the Hedgehog signalling pathway, offering potential for regenerative medicine applications.
May 2025 in “Orphanet Journal of Rare Diseases” This review suggests that immunomodulators, including TNF-α blockers and IL inhibitors, may improve symptoms of moderate-to-severe dissecting cellulitis of the scalp, but their effects on hair regrowth and scarring remain unclear.
This study examined a mouse model of androgenetic alopecia and found that treatment with PRP-exosomes, alone or in combination with minoxidil, led to improved hair growth and reduced IL-6 expression compared to controls.
December 2024 in “Kufa Medical journal” The study reported that patients with alopecia areata had significantly higher serum levels of IL-17A and IL-2 compared to healthy controls, suggesting these interleukins may play an important role in the disease, though they did not correlate with its severity or duration.
October 2024 in “Benha Medical Journal” In this case-control study, researchers found that patients with alopecia areata had significantly higher serum levels of interleukin-18 and NLRP3 compared to healthy controls, suggesting a potential link between these inflammatory markers and the disease.
October 2024 in “South Eastern European Journal of Public Health” This study on women aged 18–40 with polycystic ovary syndrome reported that a three-month treatment involving dietary changes, oral contraceptives, fertility drugs, and supplements significantly improved ovulation, menstrual regularity, BMI, and reduced hirsutism, acne, and certain immune factors compared to pre-treatment and control groups.
September 2024 in “South Eastern European Journal of Public Health” This study found that a treatment regimen including dietary changes, oral contraceptives, fertility drugs, Glucophage or Metformin, and nutritional supplements significantly improved hormonal and immune markers and reduced clinical symptoms like ovulation and menstrual disorders in PCOS patients over three months.
September 2024 in “South Eastern European Journal of Public Health” This study found that patients with alopecia areata had increased levels of serum immunoglobulin E and interleukin-13 compared to healthy controls, with additional variation in levels observed across age and weight.
September 2024 in “Journal of the Pakistan Medical Association” In this experimental study, laser irradiation significantly altered the gene expression of cytokines in cultured human T-cell lymphocytes, suggesting that such laser light may photobiomodulate cytokine production in vitro.
August 2024 in “Qucosa (Saxon State and University Library Dresden)” In this study on mice, researchers observed that dermal white adipose tissue (dWAT) plays a key role in regulating skin inflammation and tissue repair; however, reduced expression of certain cytokines in obese mice may hinder these processes, indicating potential metabolic disruptions in dWAT during inflammation.
January 2024 in “International Journal of Dermatology” This commentary piece identifies interleukin-13 as a potential therapeutic target for treating alopecia areata associated with atopic dermatitis, although specific study results or outcomes are not provided in the abstract.